A Triple Therapeutic Regiment Consisted of Colchicine, Thalidomide and Total Glucosides of Paeony Is Effective and Well‐Tolerated for Treating Mucocutaneous Involvement in Patients With Behcet's Disease
ABSTRACT Objective This study aimed to investigate the efficacy and safety of a triple therapy consisting of colchicine, thalidomide and total glucosides of paeony (TGP) in Behcet's disease (BD) patients with mucocutaneous involvement. Methods Totally 355 newly diagnosed BD patients with mucocu...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-12-01
|
| Series: | Immunity, Inflammation and Disease |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/iid3.70057 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850252448248102912 |
|---|---|
| author | Jian‐Fei Cai Ya‐Rong Wei Yong Chen Jun Zou Shen Yan Jian‐Long Guan |
| author_facet | Jian‐Fei Cai Ya‐Rong Wei Yong Chen Jun Zou Shen Yan Jian‐Long Guan |
| author_sort | Jian‐Fei Cai |
| collection | DOAJ |
| description | ABSTRACT Objective This study aimed to investigate the efficacy and safety of a triple therapy consisting of colchicine, thalidomide and total glucosides of paeony (TGP) in Behcet's disease (BD) patients with mucocutaneous involvement. Methods Totally 355 newly diagnosed BD patients with mucocutaneous involvement were recruited, who received dexamethasone and colchicine for the first 2 weeks, then they were categorized into “sustained triple‐therapy (ST)” (n = 231) and “colchicine to triple‐therapy (CT)” (n = 124) groups respectively: for ST group, patients received colchicine, thalidomide plus TGP from Month (M)0.5 to M12; for CT group, patients received colchicine from M0.5 to M2, then switched to colchicine, thalidomide plus TGP from M3 to M12. Results The percentages of oral ulceration (at M1, M2) and genital ulceration (at M1) were lower in ST group compared to CT group, whereas there was no difference of other clinical manifestations (including uveitis, erythema nodosum, thrombosis, arterial involvement or nervous system involvement) at each time point between the two groups. For biochemical indexes, ESR was higher at M1 but rapidly reduced at M2 in ST group compared to CT group, while CRP level was similar at all time points between the two groups. For side effects, occurrences of drug‐related cytopenia and diarrhea were increased, in ST group compared to CT group. Conclusions A triple therapy consisting of colchicine, thalidomide and TGP is more effective and equally tolerated compared to colchicine alone in treating BD patients with mucocutaneous involvement. |
| format | Article |
| id | doaj-art-0c24525cc12b44dd9024efbd2fc8f184 |
| institution | OA Journals |
| issn | 2050-4527 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Wiley |
| record_format | Article |
| series | Immunity, Inflammation and Disease |
| spelling | doaj-art-0c24525cc12b44dd9024efbd2fc8f1842025-08-20T01:57:39ZengWileyImmunity, Inflammation and Disease2050-45272024-12-011212n/an/a10.1002/iid3.70057A Triple Therapeutic Regiment Consisted of Colchicine, Thalidomide and Total Glucosides of Paeony Is Effective and Well‐Tolerated for Treating Mucocutaneous Involvement in Patients With Behcet's DiseaseJian‐Fei Cai0Ya‐Rong Wei1Yong Chen2Jun Zou3Shen Yan4Jian‐Long Guan5Department of Rheumatology and Immunology Huadong Hospital Affiliated to Fudan University Shanghai ChinaDepartment of Neurology Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine Shanghai ChinaDepartment of Rheumatology and Immunology Huadong Hospital Affiliated to Fudan University Shanghai ChinaDepartment of Rheumatology and Immunology Huadong Hospital Affiliated to Fudan University Shanghai ChinaDepartment of Rheumatology and Immunology Huadong Hospital Affiliated to Fudan University Shanghai ChinaDepartment of Rheumatology and Immunology Huadong Hospital Affiliated to Fudan University Shanghai ChinaABSTRACT Objective This study aimed to investigate the efficacy and safety of a triple therapy consisting of colchicine, thalidomide and total glucosides of paeony (TGP) in Behcet's disease (BD) patients with mucocutaneous involvement. Methods Totally 355 newly diagnosed BD patients with mucocutaneous involvement were recruited, who received dexamethasone and colchicine for the first 2 weeks, then they were categorized into “sustained triple‐therapy (ST)” (n = 231) and “colchicine to triple‐therapy (CT)” (n = 124) groups respectively: for ST group, patients received colchicine, thalidomide plus TGP from Month (M)0.5 to M12; for CT group, patients received colchicine from M0.5 to M2, then switched to colchicine, thalidomide plus TGP from M3 to M12. Results The percentages of oral ulceration (at M1, M2) and genital ulceration (at M1) were lower in ST group compared to CT group, whereas there was no difference of other clinical manifestations (including uveitis, erythema nodosum, thrombosis, arterial involvement or nervous system involvement) at each time point between the two groups. For biochemical indexes, ESR was higher at M1 but rapidly reduced at M2 in ST group compared to CT group, while CRP level was similar at all time points between the two groups. For side effects, occurrences of drug‐related cytopenia and diarrhea were increased, in ST group compared to CT group. Conclusions A triple therapy consisting of colchicine, thalidomide and TGP is more effective and equally tolerated compared to colchicine alone in treating BD patients with mucocutaneous involvement.https://doi.org/10.1002/iid3.70057Behcet's diseasecolchicineefficacysafetythalidomidetotal glucosides of paeony |
| spellingShingle | Jian‐Fei Cai Ya‐Rong Wei Yong Chen Jun Zou Shen Yan Jian‐Long Guan A Triple Therapeutic Regiment Consisted of Colchicine, Thalidomide and Total Glucosides of Paeony Is Effective and Well‐Tolerated for Treating Mucocutaneous Involvement in Patients With Behcet's Disease Immunity, Inflammation and Disease Behcet's disease colchicine efficacy safety thalidomide total glucosides of paeony |
| title | A Triple Therapeutic Regiment Consisted of Colchicine, Thalidomide and Total Glucosides of Paeony Is Effective and Well‐Tolerated for Treating Mucocutaneous Involvement in Patients With Behcet's Disease |
| title_full | A Triple Therapeutic Regiment Consisted of Colchicine, Thalidomide and Total Glucosides of Paeony Is Effective and Well‐Tolerated for Treating Mucocutaneous Involvement in Patients With Behcet's Disease |
| title_fullStr | A Triple Therapeutic Regiment Consisted of Colchicine, Thalidomide and Total Glucosides of Paeony Is Effective and Well‐Tolerated for Treating Mucocutaneous Involvement in Patients With Behcet's Disease |
| title_full_unstemmed | A Triple Therapeutic Regiment Consisted of Colchicine, Thalidomide and Total Glucosides of Paeony Is Effective and Well‐Tolerated for Treating Mucocutaneous Involvement in Patients With Behcet's Disease |
| title_short | A Triple Therapeutic Regiment Consisted of Colchicine, Thalidomide and Total Glucosides of Paeony Is Effective and Well‐Tolerated for Treating Mucocutaneous Involvement in Patients With Behcet's Disease |
| title_sort | triple therapeutic regiment consisted of colchicine thalidomide and total glucosides of paeony is effective and well tolerated for treating mucocutaneous involvement in patients with behcet s disease |
| topic | Behcet's disease colchicine efficacy safety thalidomide total glucosides of paeony |
| url | https://doi.org/10.1002/iid3.70057 |
| work_keys_str_mv | AT jianfeicai atripletherapeuticregimentconsistedofcolchicinethalidomideandtotalglucosidesofpaeonyiseffectiveandwelltoleratedfortreatingmucocutaneousinvolvementinpatientswithbehcetsdisease AT yarongwei atripletherapeuticregimentconsistedofcolchicinethalidomideandtotalglucosidesofpaeonyiseffectiveandwelltoleratedfortreatingmucocutaneousinvolvementinpatientswithbehcetsdisease AT yongchen atripletherapeuticregimentconsistedofcolchicinethalidomideandtotalglucosidesofpaeonyiseffectiveandwelltoleratedfortreatingmucocutaneousinvolvementinpatientswithbehcetsdisease AT junzou atripletherapeuticregimentconsistedofcolchicinethalidomideandtotalglucosidesofpaeonyiseffectiveandwelltoleratedfortreatingmucocutaneousinvolvementinpatientswithbehcetsdisease AT shenyan atripletherapeuticregimentconsistedofcolchicinethalidomideandtotalglucosidesofpaeonyiseffectiveandwelltoleratedfortreatingmucocutaneousinvolvementinpatientswithbehcetsdisease AT jianlongguan atripletherapeuticregimentconsistedofcolchicinethalidomideandtotalglucosidesofpaeonyiseffectiveandwelltoleratedfortreatingmucocutaneousinvolvementinpatientswithbehcetsdisease AT jianfeicai tripletherapeuticregimentconsistedofcolchicinethalidomideandtotalglucosidesofpaeonyiseffectiveandwelltoleratedfortreatingmucocutaneousinvolvementinpatientswithbehcetsdisease AT yarongwei tripletherapeuticregimentconsistedofcolchicinethalidomideandtotalglucosidesofpaeonyiseffectiveandwelltoleratedfortreatingmucocutaneousinvolvementinpatientswithbehcetsdisease AT yongchen tripletherapeuticregimentconsistedofcolchicinethalidomideandtotalglucosidesofpaeonyiseffectiveandwelltoleratedfortreatingmucocutaneousinvolvementinpatientswithbehcetsdisease AT junzou tripletherapeuticregimentconsistedofcolchicinethalidomideandtotalglucosidesofpaeonyiseffectiveandwelltoleratedfortreatingmucocutaneousinvolvementinpatientswithbehcetsdisease AT shenyan tripletherapeuticregimentconsistedofcolchicinethalidomideandtotalglucosidesofpaeonyiseffectiveandwelltoleratedfortreatingmucocutaneousinvolvementinpatientswithbehcetsdisease AT jianlongguan tripletherapeuticregimentconsistedofcolchicinethalidomideandtotalglucosidesofpaeonyiseffectiveandwelltoleratedfortreatingmucocutaneousinvolvementinpatientswithbehcetsdisease |